2015 Press Releases

2015 Press Releases
Home / 2015 Press Releases

2015 Press Releases

Nov-16-2015

Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting With FDA

Clear Path for Biologics License Application (BLA) Submission One Short-Term Safety and Efficacy Study Required to Support Full Approval In Parallel, Protalix to Conduct Phase III Head-to-Head Superiority Trial Comparing PRX-102 Versus Fabrazyme® CARMIEL, Israel, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it recently held an End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) to discuss the Com... 
Nov-09-2015

Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results

Net losses narrowed Recent sale of Company's Share in Collaboration and Equity Issuance to Pfizer Yielding a Total of $46 Million to Help Aggressively Push all Three Product Candidates CARMIEL, Israel, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the third quarter of 2015. "The past three months have been very exciting for the company with positive clinical data shown in PRX-102 and PRX-106," sai... 
Oct-19-2015

Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease

Significantly Improved PK Characteristics Result in: Higher Active Enzyme Quantities, Induced Immune Tolerance Meaningful Clinical Benefit Demonstrated Across All Key Disease Parameters Reversal in eGFR Slope Achieved Suggesting Improvement in Kidney Function CARMIEL, Israel, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive long term data from the 0.2mg, or lowest dose, of the Company's phase I/II dose ranging c... 
Oct-13-2015

Protalix BioTherapeutics Sells Its Share in Collaboration Agreement for ELELYSO and a 6% Equity Stake in Protalix to Pfizer for a Total of $46 Million

Protalix to Use Funds to Aggressively Push Its Clinical Pipeline Forward and Execute Its New Strategy of Developing Clinically Superior Biologics Protalix Receives All Rights to ELELYSO in Brazil in Exchange for All Rights to ELELYSO in Israel CARMIEL, Israel, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company sold its share in the collaboration agreement for ELELYSOTM to its commercialization partner, Pfizer... 
Oct-05-2015

Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF

Positive Pre-Clinical Data for PRX-106 Oral Anti-TNF in NASH CARMIEL, Israel, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today pre-clinical data for PRX-106 in Non-alcoholic Steatohepatits (NASH), a liver disease characterized by an accumulation of fat, along with inflammation and degeneration of hepatocytes. PRX-106 is the Company's orally administered, plant cell-expressed recombinant anti-TNF fusion protein that successfully concluded... 
Sep-09-2015

Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease

Positive efficacy data across all disease parameters Positive safety data with low level of antibody formation End of Phase II meeting with FDA scheduled before year end CARMIEL, Israel, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim data from the Company's phase I/II clinical trial of 1mg/kg of PRX-102 for the treatment of Fabry disease. PRX-102 is a recombinant plant cell expressed, chemically modified ve... 
Aug-10-2015

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

Net Losses Narrowed With Clinical Progress in All Three Product Candidates CARMIEL, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the second quarter of 2015. "We recently reported positive Phase I results for PRX-106 (oral Anti-TNF), with exciting results showing biological activity in the gut and activation of regulatory T cells," said Moshe Manor, Protalix's President and Chief Executive Officer. "W... 
Aug-03-2015

Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results for PRX-106 Oral Anti-TNF

Favorable Safety and Tolerability Data Demonstrates Biological Activity in the Gut and Activation of Regulatory T Cells CARMIEL, Israel, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive clinical study results from the Company's Phase I trial of PRX-106, an orally administered plant cell-expressed recombinant anti-TNF fusion protein. PRX-106 demonstrated a favorable safety and tolerability profile and biological activity in the g... 
Jun-12-2015

Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference

CARMIEL, Israel, June 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that pre-clinical data for AIR DNaseTM (PRX-110) for the treatment of Cystic Fibrosis will be presented at the 38th European Cystic Fibrosis Conference being held June 10-13 in Brussels, Belgium. AIR DNase is the Company's inhaled, chemically-modified, plant cell-expressed recombinant form of human deoxyribonuclease I, or DNase, that is resistant to actin, a potent inhibito... 
May-14-2015

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

CARMIEL, Israel, May 14, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at the 2015 UBS Global Healthcare Conference and the Jefferies 2015 Global Healthcare Conference. Details regarding the presentations are as follows: 2015 UBS Global Healthcare Conference Wednesday, May 20, 2015 at 10:30 AM ET ... 
May-07-2015

Protalix BioTherapeutics Reports First Quarter 2015 Financial Results

- Losses narrowed by 19% - Interim data and full results for PRX-102 expected in the Second Half of 2015 CARMIEL, Israel, May 7, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the quarter ended March 31, 2015. "We continue to execute on our strategy for accelerated growth, which centers on developing products with clinically superior profiles and clear competitive advantages," said Moshe Manor, Protalix's Presid... 
Mar-12-2015

Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provides Corporate Update

CARMIEL, Israel, March 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the year ended December 31, 2014 and provided an update on recent corporate developments. Financial Results for the Year Ended December 31, 2014 Total revenues for the full year ended December 31, 2014 were $13.7 million compared to $10.5 million for the full year ended December 31, 2013. Elelyso™ revenues from sales of the product i... 
Feb-12-2015

Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at the WORLD Symposium

New Positive Clinical Data on Cardiac and Kidney Functions Detailed Positive Clinical Data on All Disease Parameters CARMIEL, Israel, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that additional positive interim data from the Company's phase I/II dose-ranging clinical trial of PRX-102 for the treatment of Fabry disease will be presented on February 12, 2015 at 10:45 AM ET at the Lysosomal Disease Network WORLD Symposium in Or... 
Feb-02-2015

Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease

Interim Efficacy and Safety Results to be Presented at WORLD Symposium CARMIEL, Israel, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company has completed enrollment in its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. All patients that completed the trial have opted to continue to receive PRX-102 in an open-label extension trial. PRX-102 is a proprietary plant cell-expressed, chemically modified r... 
Jan-08-2015

Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease

Meaningful Clinical Benefits Demonstrated Across All Key Disease Parameters Favorable Safety Profile CARMIEL, Israel, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim efficacy and safety data from the Company's ongoing phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 demonstrated meaningful clinical benefits across the following key disease parameters already in the low dose of 0.2... 
Jan-05-2015

Protalix BioTherapeutics to Present at the 2015 J.P. Morgan Healthcare Conference

CARMIEL, Israel, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 11:30 AM PT. The conference will be held at the Westin St. Francis Union Square Hotel in San Francisco on January 12-15, 2015. A live webcast of the presentation will be available at ww... 
Jan-05-2015

Protalix BioTherapeutics Announces New Strategy for Accelerated Growth

Prioritizing Pipeline Candidates to Focus on Bio-Better Products With a Clear Competitive Advantage CARMIEL, Israel, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today the Company's newly implemented strategy for accelerated growth. The strategy centers around prioritizing existing and new pipeline candidates to focus on bio-better products with potentially clinically superior profiles that offer a clear competitive advantage. The followin...